Am I Eligible?

You may qualify for the AIRFLOW-4 Clinical Trial if you:

- ✓ Have been diagnosed with COPD and take daily medications to manage your symptoms
- ✓ Are between 40 and 80 years of age
- ✓ Experience frequent COPD symptoms that interfere with your daily life activities
- ✓ Do not currently smoke, and do not plan to start again
- ✓ Have significant lung hyperinflation with minimal amounts of emphysema, as determined by your lung function tests and a chest CT scan

The study doctor or staff will review an Informed Consent Form with you, which explains the study therapy and the study in detail, any known risks or benefits, your rights as a participant and other information you may need to make a decision.

For additional information, please contact a study representative or visit **www.AirflowTrial.com**

SCAN ME

If your COPD medications just aren't enough, a one-time treatment might help.

To learn more about the COPD Investigational study, go to www.airflowtrial.com or contact a study representative at:

Interested? Learn More Today.

NUVAIRA®

1. Undem, Kollarik, The Role of Vagal Afferent Nerves in COPD, Proceedings of the American Thoracic Society, 2005.
2. Common potential risks associated with the dNerva procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.

dNerva Lung Denervation System is an investigational device.

V5, March 2026; MCA-0249_A_0326

A New One-Time Treatment for COPD

AIRFLOW 4
CLINICAL TRIAL

About the Therapy

In people with COPD, overactive airway nerves contribute to daily symptoms such as worsening of mucus, chest tightness and difficulty breathing[1]. While medications can help manage COPD, some patients continue to experience frequent symptoms that interfere with their daily activities and quality of life.

The AIRFLOW-4 Clinical Trial is evaluating the dNerva® Lung Denervation System, an investigational device, which is designed to improve lung function, reduce shortness of breath, and reduce flare-ups of COPD. The treatment is a one-time procedure to ablate the pulmonary nerves that contribute to worsening of COPD symptoms. The procedure involves a bronchoscopy in the main airway of each of the lungs. Over 500 patients, including in the United States, have already been treated with the dNerva therapy in clinical trials.

The dNerva procedure:

- One outpatient treatment that takes about one hour
- No lung implants left behind
- Performed in a hospital under general anesthesia (patients are asleep during the procedure)
- Most patients go home the same day

What to expect on procedure day:

Your medical team will:

- Give you medication to ensure you sleep through the procedure
- Insert a standard bronchoscope through your mouth to access the main airways of your lungs
- Place a catheter in your esophagus (the tube connecting your throat to your stomach) to keep your esophagus cool during the treatment
- Inflate a specialized catheter to keep your airways cool while the treatment energy is delivered to the nerves on the outside of your airways
- After the treatment, you will wake up and will likely be able to return home later the same day



Narrowed airway before dNerva treatment



Opened airway after dNerva treatment

No Study costs

All study-related visits and tests, including the dNerva treatment, are provided at no cost to you. Your travel expenses for study visits can be reimbursed.

Study visits and phone visits may also be compensated, depending on the study site.

Time Commitment for Study Participation

AIRFLOW-4 patients will be followed for two years. The study is randomized, which means that half of the participants will receive the dNerva treatment in addition to continuing with their daily COPD medications (treatment group), and half of the participants will continue with their daily COPD medications without the dNerva treatment (control group).

After one year, participants in the control group will have the option to receive the dNerva treatment free-of-charge.

- All participants will visit the hospital for necessary screening tests
- Patients in the treatment group will visit the hospital for the dNerva procedure
- Three phone-call visits and six in-person visits over two years

Potential benefits and risks

Patients receiving dNerva treatment may potentially experience improvements in lung function, improvements in breathlessness, and fewer or less severe COPD symptoms including flare-ups. As with any procedure, there are potential risks associated with the treatment[2].